Skip to main content
. 2021 Jul 7;13(7):1040. doi: 10.3390/pharmaceutics13071040

Figure A2.

Figure A2

Efficacy of the anti-TCR CDR3 mRNA vaccine in vivo. The experiment presented in Figure 2 was repeated and gave a similar result: mice vaccinated with the mRNA (five C57BL/6 mice) encoding the EL4 TCR CDR3s had a significant (2way ANOVA p value 0.0008) delay in tumour growth compared to untreated (six C57BL/6 mice).